Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

[German-Austrian recommendations for HIV treatment during pregnancy and for newborns exposed to HIV--Update 2008].

Gemeinsame Erklärung* der Deutschen AIDS-Gesellschaft (DAIG); Osterreichischen AIDS-Gesellschaft (OAG); Kompetenznetzes HIV/AIDS sowie des Robert-Koch-Institutes Berlin (RKI); Deutschen Arbeitsgemeinschaft niederniedergelassener Arzte in der Versorgung von HIV-und AIDS-Patienten (DAGNA); Deutschen Gesellschaft für Kinderheilkunde und Jugendmedizin (DGKJ); Pädiatrischen Arbeitsgemeinschaft AIDS Deutschland (PAAD); Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG); Nationalen Referenzzentrums für Retroviren (NRZ) der Deutschen AIDS-Hilfe (DAH).

Dtsch Med Wochenschr. 2009 Jan;134 Suppl 1:S40-54. doi: 10.1055/s-0028-1123974. Epub 2009 Jan 26. Review. German. No abstract available.

PMID:
19172555
2.

Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.

Anderson GD.

Clin Pharmacokinet. 2005;44(10):989-1008. Review.

PMID:
16176115
3.

Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting.

González de Requena D, Bonora S, Garazzino S, Sciandra M, D'Avolio A, Raiteri R, Marrone R, Boffito M, De Rosa FG, Sinicco A, Di Perri G.

Antimicrob Agents Chemother. 2005 Sep;49(9):3966-9.

4.

Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies.

Muro E, Droste JA, Hofstede HT, Bosch M, Dolmans W, Burger DM.

J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):419-21.

PMID:
16010163
5.

Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy.

Barrett JS, Labbé L, Pfister M.

Clin Pharmacokinet. 2005;44(6):591-625. Review.

PMID:
15910009
6.

Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study.

Crommentuyn KM, Huitema AD, Brinkman K, van der Ende ME, de Wolf F, Beijnen JH; Athena study.

J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):249-50. No abstract available.

PMID:
15905743
7.

Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.

Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD; 2NN Study Group.

Antivir Ther. 2005;10(1):145-55.

PMID:
15751772
8.

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.

Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford C, Shaw A, Quinn J, Gish RG, Rousseau F.

J Infect Dis. 2005 Mar 15;191(6):825-9. Epub 2005 Feb 10.

PMID:
15717255
9.

Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.

Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, Mulcahy FM.

AIDS. 2005 Jan 3;19(1):63-7. Erratum in: AIDS. 2007 Jul 31;21(12):1671.

PMID:
15627034
10.

Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients.

Stocker H, Kruse G, Kreckel P, Herzmann C, Arastéh K, Claus J, Jessen H, Cordes C, Hintsche B, Schlote F, Schneider L, Kurowski M.

Antimicrob Agents Chemother. 2004 Nov;48(11):4148-53.

11.

Nevirapine in the treatment of HIV.

Milinkovic A, Martínez E.

Expert Rev Anti Infect Ther. 2004 Jun;2(3):367-73. Review.

PMID:
15482202
12.

Race is not associated with nevirapine pharmacokinetics.

de Maat MM, Nellen JF, Huitema AD, Wit FW, Mulder JW, Prins JM, Beijnen JH.

Ther Drug Monit. 2004 Aug;26(4):456-8.

PMID:
15257078
13.

Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance.

Mackie NE, Fidler S, Tamm N, Clarke JR, Back D, Weber JN, Taylor GP.

HIV Med. 2004 May;5(3):180-4.

14.

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.

Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL.

J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S21-33.

PMID:
14562855
15.

Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women.

Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT.

AIDS. 2003 May 23;17(8):1195-9.

PMID:
12819521
16.

Analysis of generic nevirapine products in developing countries.

Penzak SR, Acosta EP, Turner M, Tavel JA, Masur H.

JAMA. 2003 May 28;289(20):2648-9. No abstract available.

PMID:
12771111
17.

Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation.

Heikkinen T, Ekblad U, Palo P, Laine K.

Clin Pharmacol Ther. 2003 Apr;73(4):330-7.

PMID:
12709723
18.

U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.

Mofenson LM; Centers for Disease Control and Prevention, U.S. Public Health Service Task Force.

MMWR Recomm Rep. 2002 Nov 22;51(RR-18):1-38; quiz CE1-4.

19.

Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals.

De Maat MM, Mathôt RA, Veldkamp AI, Huitma AD, Mulder JW, Meenhorst PL, Van Gorp EC, Carlier H, Beijnen JH.

Pharmacol Res. 2002 Sep;46(3):295-300.

PMID:
12220974
20.

Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.

van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM.

Antivir Ther. 2001 Dec;6(4):201-29. Review.

PMID:
11878403

Supplemental Content

Support Center